Babatunde O. Oyajobi, M.D., Ph.D., M.B.A.

Abstract

Wang H, Xiao L, Zhang H, Sun W, Ebetino FH, Boeckman RK Jr, Oyajobi B, Boyce BF, Xing L. Bone-targeted bortezomib prevents OVX- and myeloma-induced bone loss with less systemic adverse effects more effectively than bortezomib (PLENARY Poster: Annual Meeting of American Society for Bone and Mineral Research, Atlanta, GA; abstract # FR0312); 2016 Sep. Merkel A, Uppuganti S, Rowland B, Oyajobi B, Nyman J, Sterling J. Transforming growth factor beta inhibitor (1D11) combined with Bortezomib improves bone quality in a mouse model of myeloma-induced bone disease. (ORAL Presentation: Annual Meeting of American Society for Bone and Mineral Research, Atlanta, GA; abstract; 2016 Sep. Medina EA, Polusani SR, Oberheu K, Oyajobi BO. PKA/AMPK signaling is a mediator of the anti-proliferative effect of adiponectin on multiple myeloma cells; 2014 Apr. (5th Annual Frontiers of Translational Science Research Day, UTHSCSA). Medina EA, Polusani SR, Oberheu K, Oyajobi BO. PKA/AMPK signaling in relation to the anti-proliferative effect of adiponectin on multiple myeloma. (Poster: 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA; (abstract # 2437); 2014 Apr. (2014 Proceedings of the AACR).

Journal Article

Gupta A*, Sharma R*, Wideman C*, Williams PJ, Tabassi R, McCluskey B, Bhaskaran S, Saenz-Flores A, Oyajobi BO (Corresponding author). Bortezomib prolongs survival in an in vivo murine model of multiple myeloma. (*Equal contribution) To be submitted to British Journal of Haematology 2019 Aug;. Khoo WH, Ledergor G, Weiner A, Roden DL, Terry RL, McDonald MM, Chai RC, Veirman K, Owen KL, Opperman KS, Vandyke K, Clark JR, Seckinger A, Kovacic N, Nguyen A, Mohanty ST, Pettitt JA, Xiao Y, Corr AP, Seeliger C, Novotny M, Lasken R, Nguyen TV, Oyajobi BO, Aftab DT, Swarbrick A, Parker B, Hewett D, Hose D, Vanderkerken K, Zannettino ACW, Amit I, Phan TG, Croucher PI.
. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells [Highlighted in (a) Blood Editorial Commentary: "Myeloma sleeper agent in myeloid disguise", pg 3-4 ; (b) "Key to targeting dormant cancer cells" ScienceDaily, 25 April 2019] Blood 2019 Jul;134(1):30-43. Polusani SR, Cortez V, Esparza J, Nguyen HN, Velagaleti GVN, Fan H, Kinney MC, Oyajobi BO, Habib S, Asmis R, Medina EA. Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma. Revised version re-submitted to Hematologica 2019 Feb;. Wang, H, Xiao L, Tao J, Srinivasan V, Boyce BF, Ebetino FH, Oyajobi BO, Boekman RK, Xing L. Synthesis of a bone-targeted bortezomib with in vivo anti-myeloma effects in mice Pharmaceutics 2018 Sep;10(3). McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI. Inhibiting the osteocyte specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma Blood 2017 Jun;129(26):3452-3464. Nyman JS, Merkel AR, Uppuganti S, Nayak B, Rowland B, Makowski AJ, Oyajobi BO, Sterling JA. Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease Bone 2016 Oct;91(10):81-91. Paiva B, Azpilikueta A, Puig N, Ocio EM, Sharma R, Oyajobi BO, Labiano S, San-Segundo L, Rodriguez A, Aires-Mejia I, Rodriguez I, Escalante F, de Coca AG, Barez A, San Miguel JF, Melero I. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma Leukemia 2015 Oct;29(10):2110-2113. Sharma R,* Williams PJ,* Gupta A, McCluskey B, Bhaskaran S, Mu?oz S, Oyajobi BO (Corresponding author). A dominant-negative F-box-deleted mutant of the E3 ubiquitin ligase, beta-TrCP1/FWD1 markedly reduces myeloma cell growth and survival in mice. (*Equal contribution) Oncotarget 2015 Aug;6(25):21589-21602. De Veirman K, Van Ginderachter JA, Lub S, De Beule N,Thielemans K, Bautmans I, Oyajobi BO, De Bruyne E, Menu E, Lemaire M, Van Riet I, Vanderkerken K, Van Valckenborgh E. Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells Oncotarget 2015 Mar;6(12):10532-10547. Medina EA, Oberheu K, Polusani SR, Ortega V, Velagaleti GVN, Oyajobi BO
. PKA/AMPK signaling in relation to the anti-proliferative effect of adiponectin on multiple myeloma. [Highlighted in (i) Association of American Cancer Institutes Update June 2014; (ii) Science Daily, news release 05/14/14 Leukemia 2014 Oct;28(10):2080-2089. Sou K, Goins B, Oyajobi BO, Travi BL, Phillips WT. Bone marrow-targeted liposomal carriers Expert Opinion on Drug Delivery 2011 Mar;8(3):317-328.

Other

Munoz S, Goins B, Munoz S, Armstrong A, Kakonen R, Williams PJ, Gupta A, Story B, Grubbs B, Dougall WC, Garrett IR, Phillips WT, Mundy GR, Oyajobi BO. Whole body optical imaging of green fluorescent protein (GFP)-expressing myeloma timors in the 5TGM1 model of human multiple myeloma bone disease: Comparison with 16F-FDG-PET scans (manuscript in preparation) Molecular Imaging 2015 Jan;.